Mersana Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
05 janv. 2022 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Named to 2021 List of Top Places to Work in Massachusetts by The Boston Globe
02 déc. 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Participate in the Upcoming 4th Annual Evercore ISI HealthCONx Conference
23 nov. 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at the Upcoming Stifel 2021 Virtual Healthcare Conference
10 nov. 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
09 nov. 2021 06h00 HE
|
Mersana Therapeutics, Inc.
Reported updated data from the UpRi ovarian cancer expansion cohort further bolstering confidence in UPLIFT registration strategyIntroduced UP-NEXT, a Phase 3 study of UpRi monotherapy maintenance in...
Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2021 Financial Results and Business Updates
02 nov. 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
27 oct. 2021 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership
25 oct. 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Target and Presents New Preclinical Data for XMT-2056, First Immunosynthen STING-Agonist ADC, at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
07 oct. 2021 16h05 HE
|
Mersana Therapeutics, Inc.
Preclinical data demonstrate that XMT-2056 activates the STING pathway in a target-dependent manner in both tumor cells and tumor-resident immune cells and is significantly more efficacious in...
Mersana Therapeutics to Announce Target and Present New Preclinical Data for XMT-2056 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
30 sept. 2021 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...